These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33997167)

  • 1. Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistance.
    Tung KL; Chen KY; Negrete M; Chen T; Safi A; Aljamal AA; Song L; Crawford GE; Ding S; Hsu DS; Shen X
    Genes Dis; 2021 Mar; 8(2):203-214. PubMed ID: 33997167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
    Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
    J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JUNB mediates oxaliplatin resistance via the MAPK signaling pathway in gastric cancer by chromatin accessibility and transcriptomic analysis.
    Li S; Wei Y; Sun X; Liu M; Zhu M; Yuan Y; Zhang J; Dong Y; Hu K; Ma S; Zhang X; Xu B; Jiang H; Gan L; Liu T
    Acta Biochim Biophys Sin (Shanghai); 2023 Nov; 55(11):1784-1796. PubMed ID: 37337631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
    Chen G; Gong T; Wang Z; Wang Z; Lin X; Chen S; Sun C; Zhao W; Kong Y; Ai H; Yang H; Liu Y; Wu F; Kang J; Zhao S; Xiao X; Sun J; He A; Li Z
    Cell Oncol (Dordr); 2022 Dec; 45(6):1155-1167. PubMed ID: 36136268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Resistance Biomarkers in Patient-Derived Colorectal Cancer Organoid and Fibroblast Co-Culture System.
    Ryu KB; Seo JA; Lee K; Choi J; Yoo G; Ha JH; Ahn MR
    Curr Issues Mol Biol; 2024 Jun; 46(6):5794-5811. PubMed ID: 38921017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction".
    Papaccio F; García-Mico B; Gimeno-Valiente F; Cabeza-Segura M; Gambardella V; Gutiérrez-Bravo MF; Alfaro-Cervelló C; Martinez-Ciarpaglini C; Rentero-Garrido P; Zúñiga-Trejos S; Carbonell-Asins JA; Fleitas T; Roselló S; Huerta M; Sánchez Del Pino MM; Sabater L; Roda D; Tarazona N; Cervantes A; Castillo J
    J Exp Clin Cancer Res; 2023 Jan; 42(1):8. PubMed ID: 36604765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids.
    Li Q; Sun H; Luo D; Gan L; Mo S; Dai W; Liang L; Yang Y; Xu M; Li J; Zheng P; Li X; Li Y; Wang Z
    J Exp Clin Cancer Res; 2021 Nov; 40(1):348. PubMed ID: 34740372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity.
    Shi X; Li Y; Yuan Q; Tang S; Guo S; Zhang Y; He J; Zhang X; Han M; Liu Z; Zhu Y; Gao S; Wang H; Xu X; Zheng K; Jing W; Chen L; Wang Y; Jin G; Gao D
    Nat Commun; 2022 Apr; 13(1):2169. PubMed ID: 35449156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform.
    Forsythe SD; Sasikumar S; Moaven O; Sivakumar H; Shen P; Levine EA; Soker S; Skardal A; Votanopoulos KI
    Ann Surg Oncol; 2020 Dec; 27(13):4950-4960. PubMed ID: 32632882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromatin Remodeling in Patient-Derived Colorectal Cancer Models.
    Xiang K; Wang E; Mantyh J; Rupprecht G; Negrete M; Sanati G; Hsu C; Randon P; Dohlman A; Kretzschmar K; Bose S; Giroux N; Ding S; Wang L; Balcazar JP; Huang Q; Sundaramoorthy P; Xi R; McCall SJ; Wang Z; Jiang C; Kang Y; Kopetz S; Crawford GE; Lipkin SM; Wang XF; Clevers H; Hsu D; Shen X
    Adv Sci (Weinh); 2024 Apr; 11(16):e2303379. PubMed ID: 38380561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of SUV420H2-Dependent Chromatin Compaction Drives Right-Sided Colon Cancer Progression.
    Boonsanay V; Mosa MH; Looso M; Weichenhan D; Ceteci F; Pudelko L; Lechel A; Michel CS; Künne C; Farin HF; Plass C; Greten FR
    Gastroenterology; 2023 Feb; 164(2):214-227. PubMed ID: 36402192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailored chemotherapy for colorectal cancer peritoneal metastases based on a drug-screening platform in patient-derived organoids: a case report.
    Prieto I; Barbáchano A; Rodríguez-Salas N; Viñal D; Cortés-Guiral D; Muñoz A; Fernández-Barral A
    J Gastrointest Oncol; 2023 Feb; 14(1):442-449. PubMed ID: 36915469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
    Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
    Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients.
    Geevimaan K; Guo JY; Shen CN; Jiang JK; Fann CSJ; Hwang MJ; Shui JW; Lin HT; Wang MJ; Shih HC; Li AF; Chang SC; Yang SH; Chen JY
    Front Oncol; 2022; 12():883437. PubMed ID: 35719949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance.
    Harada K; Sakamoto N; Ukai S; Yamamoto Y; Pham QT; Taniyama D; Honma R; Maruyama R; Takashima T; Ota H; Takemoto Y; Tanabe K; Ohdan H; Yasui W
    Gastric Cancer; 2021 Nov; 24(6):1264-1277. PubMed ID: 34272617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer.
    Boos SL; Loevenich LP; Vosberg S; Engleitner T; Öllinger R; Kumbrink J; Rokavec M; Michl M; Greif PA; Jung A; Hermeking H; Neumann J; Kirchner T; Rad R; Jung P
    Cell Mol Gastroenterol Hepatol; 2022; 13(2):517-540. PubMed ID: 34700030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Drug-Response Prediction Model of APC Mutant Colon Cancer Patient-Derived Organoids for Precision Medicine.
    Shin YJ; Jo EH; Oh Y; Kim DS; Hyun S; Yu A; Hong HK; Cho YB
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Proteome Profiles of Healthy and Tumor Human Colon Organoids Reveal Both Individual Diversity and Basic Features of Colorectal Cancer.
    Cristobal A; van den Toorn HWP; van de Wetering M; Clevers H; Heck AJR; Mohammed S
    Cell Rep; 2017 Jan; 18(1):263-274. PubMed ID: 28052255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response.
    Shen X; Zhang Y; Xu Z; Gao H; Feng W; Li W; Miao Y; Xu Z; Zong Y; Zhao J; Lu A
    Cell Death Dis; 2022 Apr; 13(4):303. PubMed ID: 35379798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture.
    Usui T; Sakurai M; Umata K; Elbadawy M; Ohama T; Yamawaki H; Hazama S; Takenouchi H; Nakajima M; Tsunedomi R; Suzuki N; Nagano H; Sato K; Kaneda M; Sasaki K
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.